Clearmind finishes enrollment for first AUD cohort in CMND-100 trial

Clearmind Medicine Inc. (Nasdaq: CMND) announced on October 27, 2026 that it had completed patient recruitment for the first segment of Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder.¹

This stage represents a shift in the study's focus. Part B is Clearmind's first time testing CMND-100 in people who have been diagnosed with AUD, after Part A was completed using healthy volunteers.¹ The design calls for two dose levels given in sequence. Part B is structured as two back-to-back single-dose cohorts at 80 mg and 160 mg, with six patients in each, intended to measure safety, tolerability, pharmacokinetics, and early indications of effect, including possible drops in alcohol craving.¹

Testing is spread across two countries. The study is running at sites in the US and Israel, among them Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.¹

CEO Adi Zuloff-Shani said completing recruitment for this part of the trial is significant because it moves the program from healthy volunteers into the patient group the company aims to treat, and said it builds on safety and tolerability findings from Part A.

Describing itself, the company said it is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.¹ It also said its goal is to turn psychedelic-based compounds into products that could be sold as regulated medicines, foods, or supplements.¹ On intellectual property, the company reported holding nineteen patent families, including 32 granted patents.¹